



ABN 53 075 582 740

ASX ANNOUNCEMENT
4 November 2016

BIONOMICS AND MSD HOSTING SYMPOSIUM FEATURING AUSTRALIAN AND INTERNATIONAL SPEAKERS

- **Symposium speakers include some of the world's most respected experts in the fields of memory, movement and mood**
- **Speakers and audience benefit from reports on latest advances in the science and treatment options for Alzheimer's Disease, Parkinson's Disease and anxiety**

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, will co-host a one-day symposium in Adelaide at the Crowne Plaza, Hindmarsh Square on Monday 7 November 2016 on *Frontiers in Neuroscience Research: Memory, Movement and Mood* featuring Australian and international experts.

Bionomics has combined with Merck & Co Inc., of Kenilworth NJ (known as Merck, Sharp and Dohme or MSD, outside the United States and Canada) to arrange the event.

This is the 4th Annual Bionomics - MSD symposium and will be the biggest to date with over 210 registrations. Attendees include researchers, medical personnel and patient support groups as well as investors and life science analysts.

The purpose of the forum is to inform and discuss the latest advances in the understanding of these conditions and treatment options.

The symposium will be opened by Bionomics CEO and Managing Director, Dr Deborah Rathjen and closed by Mr Riad El-Dada, Vice President & Managing Director, MSD Australia & New Zealand.

The keynote presentation will be by Dr David Michelson, Vice President Neuroscience & Ophthalmology, Clinical Research, MSD on *Approaching an Answer to Alzheimer's Disease? Antibodies, BACE, and Beyond*.

Bionomics' Chief Scientific Officer, Dr Jens Mikkelsen, will be presenting an overview of Bionomics' drug candidate for the treatment of anxiety disorders and the recent successful Phase 2 clinical trial results in a talk entitled *BNC210: A Next Generation Anxiolytic*.

Another notable presenter is Professor Allan Young, Chair of Mood Disorders, King's College London, Institute of Psychiatry, Psychology and Neuroscience who will speak on *Neurodegeneration*:

From Depression to Dementia. Professor Young was Principal Investigator of the recently reported, successful BNC210 Phase 2 clinical trial in patients with Generalized Anxiety Disorder (GAD).

Please find below the program. Registration is free.



Free
Registration

4th Annual Symposium

At the Frontiers of Neuroscience: Memory, Movement and Mood

Crowne Plaza, Hindmarsh Square, Adelaide
Monday 7 November 2016

Free registration (email Lauren Nicotra: lnicotra@bionomics.com.au)

Time	Speaker	Topic
9.30	TEA AND COFFEE	
	SESSION 1:	
10.00	Dr. Deborah Rathjen CEO & Managing Director, Bionomics	Welcome
10.15	Dr. David Michelson VP Neuroscience and Ophthalmology, Clinical Research, Merck Sharp & Dohme	Approaching an Answer to Alzheimer's Disease? Antibodies, BACE, and Beyond
10.50	Dr. Jens Mikkelsen Chief Scientific Officer, Bionomics Professor in Translational Neuropharmacology	BNC210: A Next Generation Anxiolytic
11.25	Prof. Allan Young Chair of Mood Disorders, King's College London, IoPPN	Neurodegeneration: From Depression to Dementia
12.00	LUNCH	
	SESSION 2:	
12.45	Prof. Bernard Baune Head of Psychiatry, University of Adelaide	Is Mental Illness at the Neuro-immune Interface?
1.20	Dr. Xiaohai Wang Principal Scientist, Neuroscience, Merck Sharp & Dohme	Increasing Protein O-GlcNAcylation as a Disease Modification Strategy for Tauopathies
1.45	Dr. Sean Smith Executive Director, Movement Disorders & Translation, Merck Sharp & Dohme	Discovery and Early Clinical Development of MK-8719, a Novel Inhibitor of OGA for the Treatment of Progressive Supranuclear Palsy (PSP)
2.10	Prof. Glenda Halliday Professor of Neuroscience, University of New South Wales	Proteinopathies causing Movement Disorders and their Clinical Relevance
2.45	AFTERNOON TEA	
	SESSION 3:	
3.10	Dr. Amjad Ali Principal Scientist, Rahway/West Point Lead Optimization Department, Merck Sharp & Dohme	Discovery and Development of Adenosine A2a Antagonists including MK-3814 (Preladenant) for the Treatment of Movement Disorders including Parkinson's Disease
3.45	Dr. Richard Hargreaves Vice President Neuropharmacology and Head Global Biomarker D&D, Biogen Idec	Deconstructing Neurodegenerative Disease using Imaging
4.20	Riad El-Dada Vice President & Managing Director, MSD ANZ	Close

FOR FURTHER INFORMATION PLEASE CONTACT:

Australia

Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

US

Stern IR, Inc.
Beth Del Giacco
+1 212 362 1200
beth@sternir.com

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder and for post-traumatic stress disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 entered clinical trials in the first quarter of 2016. Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD outside the United States and Canada) in pain and cognition.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this announcement.